by Randy E. Miller | May 28, 2025 | FDA, FOIA, Hedge Funds, Medical Devices, Stock Market
FOIAengine: Multiple Hedge Funds Seeking Inspection Reports Leading medical device manufacturer Insulet Corporation’s stock price (NASDAQ: PODD) is on a roll. But that hasn’t stopped financial firms from monitoring the company’s Food and Drug Administration plant...
by Randy E. Miller | Apr 23, 2025 | FDA, FOIA, Hedge Funds, Pharmaceuticals
FOIAengine: Questions Seek Adverse Reports about Carvykti According to a new PoliScio Analytics analysis of early 2025 Freedom of Information Act requests, investment firm Point72 has launched a significant FOIA-driven investigation into Johnson &...
by John A. Jenkins | Nov 26, 2024 | Corporate Investigators, FOIA, Hedge Funds, Law Firms, Litigation, News Media, Politics, SEC
FOIAengine: Requests Signaled Trouble for Guatam Adani Guatam Adani, India’s most powerful tycoon and a close ally of Prime Minister Narendra Modi, knows what it’s like to stare death in the face and survive. Danger has a knack for finding him. But each time – a...
by Randy E. Miller | Sep 18, 2024 | FDA, FOIA, Hedge Funds, Medical Devices
FOIAengine: FDA Inspections Prompt FOIA Requests When CEO Quentin Blackford of iRhythm Technologies, Inc. (NASDAQ: IRTC) began his earnings call on August 1, his wearable heart monitor technology company had survived five years of market ups and downs and had...
by John A. Jenkins | Jul 10, 2024 | FOIA, Hedge Funds, Litigation, SEC
FOIA Requests Reveal Perils and Possibilities of the Consolidated Audit Trail, aka “Mass Surveillance” Imagine a time when anyone might be able to file a Freedom of Information Act request with the Securities and Exchange Commission for a complete audit-trail report...
by Randy E. Miller | May 30, 2024 | FDA, FOIA, Hedge Funds, News Media, Pharmaceuticals, Stock Market
FOIAengine: Requests Show FDA Still Under Pressure This week, we’re taking a closer look at the numerous Freedom of Information Act requests recently filed with the Food and Drug Administration concerning the problematic India pharmaceutical industry. As we noted in...
